Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CERINTA vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI); enhances serotonergic neurotransmission by inhibiting serotonin reuptake at the presynaptic neuron.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Premenstrual dysphoric disorder
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
50 mg orally twice daily
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Terminal elimination half-life is 12 hours (range 10–14 h) in adults; prolonged to 24–30 h in severe renal impairment (Cr Cl <30 m L/min).
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Primarily hepatic via CYP2D6 and CYP3A4; active metabolites include N-desmethylcitalopram.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Renal (70% unchanged) and fecal (25% as metabolites); biliary excretion minimal (<5%).
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
98% bound to albumin and alpha-1-acid glycoprotein.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Vd = 0.5–0.8 L/kg, indicating distribution into total body water and some tissue binding.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral: 75–85% (first-pass metabolism reduces bioavailability from 90% to 75–85%).
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: Reduce dose to 25 mg twice daily. GFR <30 m L/min: Not recommended.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 25 mg twice daily. Child-Pugh C: Not recommended.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Safety and efficacy not established in pediatric patients.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
No specific dose adjustment; use caution due to increased risk of adverse effects.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Serotonin syndrome,QT prolongation,Hyponatremia,Activation of mania/hypomania,Seizure risk,Angle-closure glaucoma
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Concomitant use with MAOIs or within 14 days of MAOI discontinuation,Concomitant use with pimozide,Known hypersensitivity to cerinta
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
Take with food to improve absorption and reduce GI side effects. Avoid grapefruit, grapefruit juice, and Seville oranges as they are strong CYP3A4 inhibitors and can increase ceritinib levels.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
Cerinta is contraindicated in pregnancy. First trimester: High risk of neural tube defects and cardiac malformations. Second and third trimesters: Risk of oligohydramnios, fetal renal dysfunction, and skull ossification delay.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Contraindicated. Cerinta excreted in human milk; M/P ratio not established. Potential for infant nephrotoxicity and phototoxicity.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
Not applicable; contraindicated. No safe dose established. Increased volume of distribution and renal clearance in pregnancy would likely require dose escalation if used, but risk outweighs benefit.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
Cerinta (ceritinib) is a potent ALK inhibitor. Must monitor for GI toxicities (diarrhea, nausea, vomiting) and hepatotoxicity. Administer with food to reduce nausea. Avoid concurrent strong CYP3A4 inhibitors/inducers. Baseline and periodic LFTs, serum lipase, and glucose are required. May cause QTc prolongation; avoid in patients with baseline QTc >470 ms. Interstitial lung disease (ILD) is a rare but serious adverse effect; discontinue if ILD suspected.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take ceritinib exactly as prescribed, with food, at the same time each day.,Do not crush or split tablets; swallow whole.,Common side effects include diarrhea, nausea, vomiting, and abdominal pain; contact your doctor if severe or persistent.,Report any signs of liver problems (yellow skin/eyes, dark urine, severe fatigue) or pancreatitis (severe upper abdominal pain).,Avoid grapefruit juice, grapefruit, and Seville oranges during treatment.,Inform your doctor about all medications you take, including over-the-counter drugs and supplements.,Women of childbearing age must use effective contraception during treatment and for at least 2 weeks after the last dose.,Do not breastfeed while taking this medicine.,Monitor blood glucose levels regularly; report any symptoms of hyperglycemia (excessive thirst, frequent urination).,Avoid activities requiring alertness if you experience dizziness or fatigue.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CERINTA vs ALTAVERA, answered by our medical review team.
CERINTA is a Oral contraceptive that works by Selective serotonin reuptake inhibitor (SSRI); enhances serotonergic neurotransmission by inhibiting serotonin reuptake at the presynaptic neuron.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CERINTA and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CERINTA is: 50 mg orally twice daily. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CERINTA and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CERINTA is classified as Category C. Cerinta is contraindicated in pregnancy. First trimester: High risk of neural tube defects and cardiac malformations. Second and third trimesters: Risk of oligohydramnios, fetal re. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.